USFDA issues warning letter to Glenmark's Goa manufacturing facility
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
The startup plans to provide free technology to dental clinics upon registration.
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
There are no data integrity (DI) observations.
Strengthens investment in channels of the future to expand patient reach
A total of five observations for Goa and 17 for Monroe
Jamnagar’s contributions towards wellness will get a global identity with WHO’s Global Centre for Traditional Medicine
FDA changes inspection classification of the facility to Voluntary Action Indicated
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Subscribe To Our Newsletter & Stay Updated